Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Alvotech & Advanz Pharma Partner on EU Aflibercept Biosimilars

Jun 18, 2024

On 18 June 2024, Alvotech announced that it has entered into an agreement with Advanz Pharma in relation to the commercialisation in Europe of Alvotech’s AVTO6 and AVT29, biosimilars to Regeneron’s Eylea® (aflibercept) in low (2mg) and high (8mg) doses, respectively.  Advanz Pharma’s commercialisation rights are exclusive throughout Europe, except in Germany and France, where they are semi-exclusive.   

Under the agreement, Advanz Pharma is required to make an upfront payment to Alvotech, with further payments due on certain development and commercialisation milestones. 

In February 2023, Alvotech and Advanz Pharma entered into an exclusive agreement in relation to the commercialisation of AVT23, biosimilar to Novartis’ Xolair (omalizumab).  That agreement covered Europe, UK, Switzerland, Canada, Australia and New Zealand.